New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the potential to improve tuberculosis (TB) treatment when combined with pretomanid and linezolid in a treatment regimen known as “SPaL.”
Phase II clinical trial results show potential to shorten TB treatment time
